Literature DB >> 10147042

Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents.

P Gazzaniga1, L Garattini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 10147042     DOI： 10.2165/00019053-199202040-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  20 in total

1.  Should there be a moratorium on the use of cholesterol lowering drugs?

Authors:  G Davey Smith; J Pekkanen
Journal:  BMJ       Date:  1992-02-15

2.  Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

Authors:  D Coyle; K Tolley
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

3.  Economic evaluation of pharmaceuticals: science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 4.  Introduction: lipids and coronary disease--resolved and unresolved problems.

Authors:  M F Oliver
Journal:  Br Med Bull       Date:  1990-10       Impact factor: 4.291

5.  QALYs: are they enough? A health economist's perspective.

Authors:  G Mooney
Journal:  J Med Ethics       Date:  1989-09       Impact factor: 2.903

6.  Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.

Authors:  L L Martens; F F Rutten; D W Erkelens; C A Ascoop
Journal:  Am J Cardiol       Date:  1990-03-20       Impact factor: 2.778

Review 7.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 8.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

9.  Castigating QALYs.

Authors:  J Rawles
Journal:  J Med Ethics       Date:  1989-09       Impact factor: 2.903

10.  Medical costs of coronary artery disease in the United States.

Authors:  E H Wittels; J W Hay; A M Gotto
Journal:  Am J Cardiol       Date:  1990-02-15       Impact factor: 2.778
View more
  5 in total

Review 1.  Conflict of interest in industry-sponsored economic evaluations: real or imagined?

Authors:  M Barbieri; M F Drummond
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

2.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

3.  Issues in the conduct of economic evaluations of pharmaceutical products.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

Review 4.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 5.  Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Authors:  A J Coukell; M I Wilde
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.